The REPLACE 1 trial: a pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockade  by Lincoff, A.Michael et al.
16A ABSTRACTS - ACCIS2002 (Angiography & Interventional Cardiology) JACC March 6,2002 
1052-11 Serum Uric Acid Level Is an independent Predictor of 
Restenosis After Successful Percutaneous 
Transluminal Coronary Stent Implantation 
Kazuaki Kumagai, Masatake Fukunami, Tsuyoshi Shimonagata. Takahisa Yamada, Akio 
Hirata. Mitsutoshi Asai, BMakino, Hidetaka Kioka, Noritake Hoki, Osaka 
Prefectural General Hospital, Osaka, Japan. 
Background: Inflammatory activities have been shown to be associated with an 
increased risk for ischemic coronary events after percutaneous transluminal coronary 
stent implantation (PTCS). Serum uric acid (UA), reflecting oxidative radical activity 
through xanthine oxidase, might be also a potent marker for chronic inflammation. How- 
ever, it is not elucidated whether elevated UA levels would be related to target lesion res- 
tenosis (TLR) following PTCS. Therefore, we studied whether UA level might be one of 
predictors of TLR. This study included 217 consecutive patients following successful 
PTCS without renal dysfunction and without serum UA-lowering drugs. Results: During 
the follow-up period of 2 years, TLR occurred in 46 patients (21%). In patients with TLR, 
serum UA level just before PTCS were significantly higher than in patients without TLR 
(6.5i1.5 vs. 5.6+1.5mg/dl. p=O.oM)3). Patients with UA of >7.0mg/dl had a significantly 
higher TLR rate (43%) at 2 years after PTCS than that (28%) in patients with UA of 
7.0mg/dl or less (p<O.OOOl , Kaplan-Meier analysis and log-rank test). Univariate analysis 
revealed that UA level (p=O.o003), sex (p-0.09), the diameter of stent (p=O.O19), serum 
C-reactive protein level (p=O.O93) and DM (p&044) were predictive of TLR, but that 
age, smoking, hypertension, hyperlipidemia, acute coronary syndrome, prior myocardial 
infarction or medications were not. Furthermore, Cox hazard model showed that UA level 
(hazard ratio; t 34, 95% Cl; 1.09-1.64, p=O.O05), serum C-reactive protein level (hazard 
ratio; 1.62, 95% Cl; 1 .Ol-2.59, p=O.O44) and the diameter of stents (hazard ratio: 0.35, 
95%CI; 0.14-0.66, p&025) were independent predictors of TLR. Conclusion: This 
study indicates that elevated serum uric acid level just before PTCS would be a most 
powerful independent predictor of TLR following successful PTCS. 
1052-12 Does Stent Design Affect Platelet Activation? Results of 
the Platelet Activation in Stenting (PAST) Study 
PaulA.GurbeL Kevin P. Callahan, Michele J. Buczkowski, Victor L. Serebruany. Sinai 
Hospital, Baltimore, Maryland. 
BACKGROUND: Platelet activation induced by coronary artery stenting affects clinical 
outcomes and may be related to stent design. However, little is known about how platelet 
activation may be altered by the specific design of a stent. METHODS: Patients (n=53) 
were randomly assigned to stenting with a closed-cell (NIR. Boston Scientific) or open- 
cell (TETRA, Guidant) stent. Patients were treated with aspirin and were loaded with 300 
mg clopidogrel in the cath lab and received 75 mg daily thereafter. All stents were 
deployed at > 12 atm. GPllblllla inhibitors were not used. Platelet aggregation (5~ mol 
ADP and lpglml collagen): and flow cytometry (mean fluorescence intensity (MFI)) to 
multiple platelet receptors and platelet-leukocyte aggregates (CD 151 + 14) were serially 
determined at baseline, and at 2 hours (2h), 24 hours (24h). 5 days (5d) and 30 days 
(30d) post procedure.RESULTS: Stenting was successful in all patients. Markers of 
platelet activation were less following NIR implantation: 30d ADP aggregation (%) (32.3+ 
6.1 YS 44.5+ 16.9, p=.O2); 24h CD31 (136f 46 VS. ll& 46, p=.O4); 24h (104? 45 YS 91* 
31 p=.O46) and 30 d CD 151 (99f 33 vs 61f 32, p=.O3); 24h (93f 40 vs. 77i 24, p=.O16) 
and 30d CD 151+14 (64k 35 vs. 72f 31, p=.O45); 30d PAC-1 (66+ 41 vs. 72* 30, 
pz.025); and 2h (22f 13 vs 16f 5, p=.O45) and 24 h CD 107a (24i 12 vs. 17 f 4, p=.O3). 
CONCLUSIONS: In this randomized prospective trial, platelet activation; indicated by 
enhanced aggregation and expression of multiple receptors; was greater during the 30 
days following implantation of an open-versus a closed-cell stent. Stent-dependent plate- 
let activation may be relevant to the propensity for subacute thrombosis and restenosis 
associated with a particular stent design. 
POSTER SESSION 
1053 Adjunctive Drug Therapy in Percutaneous 
Interventions 
Sunday, March 17,2002, 3:00 p.m.-500 p.m. 
Georgia World Congress Center, Hall G 
Presentation Hour: 3:00 p.m.-4:OO p.m. 
1053-l Early and Sustalned Survival Benefit Associated With 
Statln Therapy at the Time of Percutaneous Coronary 
intervention 
e, Deepak L. Bhatt. Derek P. Chew, Martin J. Quinn. David J. Moliterno, 
Eric J. Topol, Stephen G. Ellis, The Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: Long-term administration of statin therapy has been shown to reduce 
major coronary events and cardiac mortality in clinical trials. Beyond lipid lowering, 
statins favorably affect platelet adhesion, thrombosis, endothelial function, inflammation, 
and plaque stability, which may potentially improve outcome after PCI. Therefore, we 
hypothesized that statin therapy has an early beneficial effect in patients undergoing PCI. 
Methods: Each year from 1993 through 1999, we prospectively collected data and fol- 
lowed our first 1.000 patients undergoing PCI. Baseline, procedural, and 6-month data of 
statin-treated and non-statin-treated patients were compared. Propensity score and mul- 
tivariate survival analysis were used to adjust for heterogeneity between the 2 groups. 
Results: Of 6,647 patients with completed follow-up, 23.5% were treated with statin at 
the time of the procedure. Statin therapy was associated with a 60% lower mortality at 30 
days (1.0% YS 2.5%. p = 0.0007) and a 37% reduction at 6 months (3.1% vs 4.9%, p = 
0.003). After adjusting for the propensity to receive statin therapy prior to the procedure 
and for other confounders, statin therapy remained an independent predictor for survival 
at 6 months following PCI (HR 0.66. 95% C.I. 0.46-0.93, p = 0.017). The mortality benefit 
was independent of p&procedural MI, recurrent MI. and target vessel revascularization. 
Conclusion: Statin therapy among PCI patients was associated with a significant mortal- 
ity lowering at early and intermediate term follow-up. The mechanism of survival benefit 
of statin beyond lipid-lowering needs further elucidation. 
1053-2 A Blinded Multicenter Dose Escalation Phase Ila Study 
of the Factor VIMIssue Factor Inhlbltor Recombinant 
Nematode Anticoagulant Protein c2 In Patients 
Undergoing Elective Percutaneous Coronary 
Intervention 
Arno H. Moon_& N. R. Bijsterveld, H. R. Biiller, M. H. Prins, W. E. Rote, G. P. Vlasuk, R. J. 
Peters, Academic Medical Center, Amsterdam, The Netherlands, Cowas International, 
San Diego, California. 
fntroductlon: A multicenter, randomized, double-blind, placebo controlled, dose escala- 
tion study in patients undergoing elective percutaneous coronary intervention (PCI) eval- 
uated the safety of recombinant Nematode Anticoagulant Protein c2 (rNAPcP), a potent 
inhibitor of the factor VII&issue factor (FVlla/TF) complex. 
Methods: Patients received either placebo or rNAPc2 from one of 4 dose groups as a 
single SC administration 2-6 hours before PCI, as well as aspirin and IV unfractionated 
heparin (activated clotting time > 250 set). The primaty endpoints were femoral com- 
pression time (FCT) after sheath removal, and incidence of major and minor bleeding. 
Secondary endpoints included the plasma concentration of prothrombin activation frag- 
ment 1+2 (Flc2) over time. 
Result% 
rNAPc2 n FCTB F1+2 (nmol/L)b Bleeding n(%) 
(pS/kg) (min) 
Bh? 24 he 36 he Minor Major 
placebo 30 10 (10-27) 1.2 (0.6) 1 .l (0.6) 1.4 (0.9) 2 (7) 0 (0) 
3.5 23 10 (10-16) 0.7 (0.3)” 0.7 (0.2)“’ 0.9 (0.3)’ 1 (4) 0 (0) 
5.0 24 10 (10-15) 0.6 (0.3)’ 0.6 (0.3)” 1.0 (0.5) 1 (4) 3 (13) 
7.5 27 10 (10-70) 0.7 (0.4)” 0.7 (0.2)“’ 0.7 (0.2)” 3 (11) t (4) 
10.0 26 16 (10-50)” 0.6 (0.7) 0.7 (0.2)” 0.7 (0.2)” 6 (31) 0 (0) 
amedian (range) bmean (SD); ‘after PCI, dafter rNAPc2; 
P-value: rNAPc2 vs placebo: ‘co.05 “<O.Ol “‘<O.OOl 
FCT and minor bleeding, but not major bleeding, demonstrated a dose-dependent 
increase. All three patients that developed major bleeding in the 5.0 pgikg dose group 
also received a glycoprotein Ilb/llla receptor antagonist. rNAPc2, regardless of dose, pro- 
duced a prolonged, significant suppression of thrombin generation as measured by 
plasma F1+2 extending over 24 hours after the single SC administration. 
Conclusions: These results suggest that FVlla/TF inhibition with rNAPc2 is a safe and 
potentially effective strategy for prevention of thrombotic complications in patients under- 
going coronary interventions. This study supports further investigation of rNAPc2 in 
patients suffering from acute coronary syndromes. 
1053-3 The REPLACE 1 Trial: A Pilot Study of Bivalirudin 
Versus Heparin During Percutaneous Coronary 
Intervention Wlth Stentlng and GP IlMlla Blockade 
A. Michael I incnff, John A. Bittl, Neal S. Kleiman, Dean J. Kereiakes, Robert A. 
Harrington, Ian J. Sarembock, J. Daniel Jackman, Sameer Mehta, Elizabeth F. Maierson, 
Derek P. Chew, Eric J. Topol, for the REPLACE Investigators. Cleveland Clinic 
Foundation, Cleveland, Ohio. 
Background: The direct thrombin inhibitor bivalirudin (previously “Hirulog”) has been 
associated with improved efficacy and less hemotiage than heparin during balloon 
angioplasty, but has not yet been widely tested with stenting or GP llblllla antagonists. 
Methods: In a pilot study, 1056 pts undergoing elective or urgent coronary intervention 
(PCI) at 77 sites in the US were randomized in a central, open-label fashion to receive 
heparin (60-70 U/kg initial bolus) or bivalirudin (0.75 mg/kg bolus, 1.75 mglkg-hr infusion 
during PCI). All pts received aspirin, and pretreatment with clopidogrel was encouraged. 
GP Ilb/llla inhibitor use was per operator preference. Endpoints were death, MI, repeat 
revascularization, or major bleeding by hospital discharge or 46 hours. 
Results: Stents were used in 65% of pts; 72% received a GP IlWllla inhibitor. Activated 
cloning times were significantly higher among pts randomized to bivalirudin than hepadn 
prior to device deployment (371 +I- 102 set vs. 304 +I- 69 set, pcO.001) and at proce- 
dure end (334 +/- 63 set vs. 267 +/- 56 sac, p-zO.001). individual endpoints and the “Tri- 
ple”(death. MI, revasc) and “Quadruple’ composites (death, MI. revasc, major bleeding) 
are detailed in the Table (all p = NS). 
Death (%) 
Ml (%) 
Repeat Revascularization (%) 
Major Bleeding (%) 
“Triple” Composite (%) 
“Quadruple” Composite (%) 
Heparin (n = 524) Bivalirudin (n = 532) 
0.6 0 
5.2 4.9 
2.3 1.5 
2.7 2.1 
6.9 5.6 
6.6 7.1 
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Conclusions: In this large pilot experience, rates of ischemic and bleeding events 
trended lower with bivalirudin than with heparin during contemporary PCI. Bivalirudin 
may be the first antithrcmbctic agent to uncouple suppression of ischemic events from 
hemorrhagic risk. 
1053-4 Reduction in Percutaneous Coronary Intervention- 
Related Bleeding With Bivalirudin Is Particularly 
Striking in Women 
&s&&&v&, Leslie Cho. A. Michael Linccff, John A. Bittl. Eric J. Tcpol, Cleveland 
Clinic Foundation, Cleveland, Ohio, Ocala Heart Institufe, Ocala, Florida. 
Background: Female gender is a known potent risk factor for post-procedural bleeding 
among patients undergoing percutaneous coronary intervention (PCI). 
Methods: Within a randomized clinical trial of coronary angioplasty comparing bivalirudin 
to unfractionated heparin (the Bivalirudin Angioplasty Trial), rates of ischemic events and 
major hemorrhage were stratified by gender. 
Results: of the 4312 patients enrolled. 1367 (32.2%) patients were women. Compared 
to males, female gender was associated with a 2.3-fold increased risk of major hemor- 
rhage - males: 131/2925 (4.5%) YS females: 144/1367 (10.4%) (pc0.0001). When strati- 
fied by treatment arm, bivalirudin was associated with a significant reduction in bleeding 
regardless of gender. However, this effect was most striking among female patients 
(Table). Considering a combined safety and efficacy endpoint of death, MI, revasculariza- 
tion. and major hemorrhage. bivalirudin was associated with a 50% relative risk reduction 
in adverse events in wcmen _ 141/690 (20.4%) vs 69/697 (9.9%) (p~O.OOOl), and a 35% 
relative risk reduction in men - 171/1461 (11.7%) vs Ill/l464 (7.6%) (p<O.WOl). 
Conclusions: Bivalirudin is associated with a substantial reduction in bleeding and 
ischemic events in both men and women. but the improved safety profile is especially 
prominent among women. Such patients with an increased risk of bleeding during PCI 
may benefit if bivalirudin is used in place of unfractionated heparin. 
Major Hemorrhage 
Heparin Bivalirudin P Value 
Women 
Men 
(I 07/690) 15.5% (37/697) 5.3% <0.@301 
(92/1461) 6.3% (39/1464) 2.7% <O.OOOl 
1053-5 A New Rapid Ecarin Clotting Time Assay but Not 
Activated Clotting Time Strongly Correlates With 
Blvallrudln Concentration: A Percutaneous Coronary 
Intervention Study 
mCho, Joel Reginelli, A. Michael Linccff, Marco Roffi, Teresa Kaldus, Kandice 
Kottke-Marchant, Patrick D. Mize, David J. Moliterno. The Cleveland Clinic Foundation, 
Cleveland, Ohio, Pharrnanetics Inc, Chapel Hi//, Ohio. 
Background: Recently, direct thrombin inhibitors (DTI) have been approved for antico- 
agulation in percutaneous coronary interventions (PCI). The accuracy of the activated 
clotting time (ACT), used for monitoring heparin. is uncertain for patients receiving DTI. A 
new point-of-care assay has been developed based on the ecarin clotting time (ECT), 
which specifically measures the activity of direct thrombin inhibitors. No prior study has 
evaluated the correlation of ECT and ACT to the direct measurement of anti Factor Ila 
activity duirng PCI. Methods: To test the accuracy of available ACT assays (Hemcchrcn 
and Pro-DM) and the rapid ECT assay (Pharmanetics), we enrolled 64 consecutive PCI 
patients receiving the DTI bivalirudin at The Cleveland Clinic. We compared point of care 
ACT and ECT to central laboratory anti Factor Ila activity levels, Anti Factor Ila activity is 
a direct measurement of bivalirudin concentration in body. Samples were tested in both 
titrated and non-titrated blood. Correlation coefficient was calculated by the Spearman 
test. Results: Bivalirudin concentration correlated well with ECT sample (rxO.76, 
p<O.OOl). In contrast, there was relatively poor correlation between bivalirudin concentra- 
tion and Hemcchrcn ACT (r=0.26, p=O.O5) or pro-DM ACT (wO.41, p<O.OOl). There was 
alsc poor correlation between ECT and Hemcchrcn ACT (r&27. p=O.O4) and ECT with 
pro-DM ACT (r=O.52, p<O.601). There was poor correlation between pro-DM ACT and 
Hemwhron ACT (w0.40. p=O.O02). Conclusion: ECT is a reliable measurement of anti- 
coagulation in patients receiving bivalirudin, while ACT has poor correlation with bivaliru- 
din concentration. Additionally there is poor correlation between ACT and ECT in such 
patients. These findings have important implications for guiding the extent of anticoagula- 
tion during PCI with DTI. 
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1054-13 Smoking, Thrombus, and Plaque in the Culprit Vessel In 
Patients With Acute Myocardlal Infarction: Angioscopic 
Findings 
Ipshiva Kurctobi, Atsushi Hirayama, Yasunori Ueda, Masahiko Shimizu, Tcmohito 
Ohtani, Kazuhisa Kodama, Osaka Police Haspita/, Osaka, Japan. 
Backgrounds, Habitual smoking is paradoxically associated with good prognosis in 
patients with acute myccardial infarction (AMI), and results in the higher successful 
thrombolytic therapy. Therefore, we investigated the hypothesis that smoking status is 
closely associated with amount of thrcmbus culprit lesion. Methods, The prevalence of 
plaques and amount of thrombus in the major coronary arteries were successfully evalu- 
ated in 62 patients (male: 55, mean age: 60.2). All patients were underwent percutane- 
ous coronary intervention (PCI), and the residual amount of thrombus after PCI were 
semi-quantatively divided into 2 groups (massive: 1x33 or little: n=29) by angioscopy. 
Furthermore, we analyzed the color of plaque an culprit lesion (4 grades from white to 
yellow), and the number of plaque in infarct related artery (IRA). Results, 65% of the 
enrolled patients were current smokers. Although baseline TIMI grade was not signifi- 
cantly changed, prevalence of collateral vessels to infarcted related artery was higher in 
smoking patients, compared with non- smoking patients (45% VS. 17%. p=O.O9). The 
massive thrcmbus was higher prevalence in smoking patients, compared with non-smok- 
ing patients (65% vs. 22%, p<O.Ol). The number of plaque in IRA (3.012.0 vs. 3.3~1.6) 
max plaque score (2.7eO.9 vs. 2.7kO.9) and the color of plaque in culprit lesion (2.7kO.9 
vs. 2.6*1 .I) were not significantly affected by smoking status. As ccronaly risk factors, 
Total cholesterol (205 vs. 160 mg/dl, ~~0.05) and triglycelide (136 vs. 114 mg/dl. ~~0.05) 
were significantly higher, and the prevalence of hypertension (50% vs. 35, p<O.l) was 
significantly lower in smoking patients. Conclusion. This is first evidence to assess the 
association of smoking status and the amount of thrcmbus in culprit lesion directly, and 
also these findings may provide the explanation of the smoker’s paradox. 
1054-14 Possible Mechanism of Coronary Thrombosis Caused 
by Vasospasm In Angiographically Nearly Normal 
Coronary Artery: Evaluation by Plaque Appearance and 
Malondlaldehyde-Modified Oxidized LDL 
&&masa Tani, lkuyoshi Watanabe, Takeshi Fujii, Kazutoshi Ishikawa, Michiaki 
Matsumcto, Takeo Anazawa, Takashi Miyamoto, Ken Nagao, Katsuo Kanmatsuse, 
Department of Cardiobgy, Nihon University Surugadai Hospital, Tokyo, Japan, 2nd 
Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan. 
Background: Investigators have that demonstrated focal vascspasm has a high inci- 
dence of acute coronary syndrome(ACS) compared with diffuse vascspasm. Recently 
circulating malondialdehyde-modified oxidized LDL(MDA-LDL) was reponed to activate 
thrombus formation .Therefcre we investigated the differences in plaque appearance and 
plasma MDA-LDL between two patterns of vascspasm .Methcds and Results: Blood 
samples were collected from aortic rcct(Ao) and coronary sinus before provocation 
of left coronary spasm After relief of spasm, IVUS study was performed and volumetric 
analyses of spasm lesions were evaluated with Netra-3D IVUS system. More abundant 
soft plaque was localized just at the lesion with focal vascspasm even in the absence of 
significant angiographic disease, whereas in diffuse vascspasm, intimal thickness 
existed diffusely along the coronary arteries. Data is presented in TableConclusions: 
Plasma MDA-LDL levels associated with triggering thrombosis were significantly ele- 
vated in the coronary circulation in focal vascspasm. Under this condition, dramatically 
increased % plaque volume during focal vascccnstriction might play an important role in 
the mechanism of thrcmbogenicity leading to ACS 
Diffuse n=20 Focal n=l5 p value 
Cs-AC difference of MDA-LDL (U/L) -6.9+/-9.0 12+/-14.9 to.05 
Vessel volume(mm3) 127.7+/-39.1 134.4+/s44.0 ns 
Lumen volume(mm3) 91.3+/-11.2 79.5+/-10.6 ns 
Plaque vclume(mm3) 30.6+/-10.2 55.2+/-10.3 <0.05 
% plaque volume(plaque volume/vessel volume) 23.9+/-9.2 40.2+/-9.6 co.05 
1054-I 5 Insulin Resistance as an Independent Predictor of 
Acute Coronary Syndrome: An Intravascular Ultrasound 
Study With Clinical Correlations 
Takashi Yoshitama. Masato Nakamura. Tan, Tsunoda, Ycko Kitagawa, Masanori Shiba, 
Suguru Yajima, Masamichi Wada. Raisuke lijima, Rintam Nakajima. Takurc Takagi. 
Hitoshi Anzai. Takahirc Nishida, Tetsu Yamaguchi, Ohashi Hospital, Jcho University, 
Tokyo, Japan. 
Background: Insulin resistance has been implicated as an important initiating factor in 
coronary atherosclerosis. However, asscciations between insulin resistance and acute 
coronary syndrome (ACS) remain unclear. 
Methods: Before intervention, 75 patients with 65 culprit lesions underwent intravascular 
ultrasound (IVUS) examination by which cross-sectional area (CSA) within the external 
elastic membrane (EEM), lumen CSA, and plaque CSA were evaluated. Positive remod- 
